secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000950170-22-024737
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health Q3 revenue up 72% to $477K; net loss $2.6M; agrees to acquire Reliefband for $33.5M
--------------------------------------------------------------------------------

- Q3 2022 revenue $477K (+72% YoY); DTC unit sales up 130%; gross margin improved 22%.
- Net loss $2.6M vs $2.3M in Q3 2021; cash and short-term investments $6.3M at Sept 30, 2022.
- Entered asset purchase agreement for Reliefband (nausea treatment devices) for $33.5M cash; expected close Q4 2022/Q1 2023.
- Manufacturing agreement with Microart to reduce ClearUP production costs; MSRP increased $20/unit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017022024737/0000950170-22-024737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017022024737/tivc-20221114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer